Pfizer's Tilrekimig Delivers Significant Skin Clearance In Phase 2 Atopic Dermatitis Study

Pfizer presented Phase 2 data showing that investigational tilrekimig produced significant improvements in skin clearance among adults with moderate-to-severe atopic dermatitis. The results support continued clinical development of the therapy, providing a positive pipeline catalyst for Pfizer, though no numerical efficacy or safety data were disclosed.